{"filings":[{"id":816116,"accession_number":"0001823239-26-000049","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2026-06-03T12:31:58+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"Maravai LifeSciences refinances credit agreement, reduces debt by ~$93M and extends maturity to 2032","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $150M term loan and $30M revolver mature June 2032; proceeds plus $98.5M cash repaid $242.9M prior debt due Oct 2027.","Interest rate at Term SOFR + 5.00% (stepdown to 4.75% if first lien net leverage ≤ 3.0x).","Financial covenant (max 6.5x leverage) applies only if revolver usage exceeds 40% of $30M commitment.","Net debt reduced from $242.9M to $150.0M; revolver provides $30M additional liquidity.","CFO Raj Asarpota cited strengthened financial foundation and preserved access to capital for growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":747036,"accession_number":"0001823239-26-000046","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2026-05-29T20:19:02+00:00","items":["5.07"],"status":"ready","headline":"Maravai shareholders elect three directors, ratify Deloitte & Touche, approve executive pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Bernd Brust (182.9M for), Gregory T. Lucier (179.5M for), Luke Marker (182.2M for) as directors for three-year terms.","Ratified Deloitte & Touche as auditor for FY2026: 234.5M for, 1.2M against, 0.3M abstain.","Approved advisory say-on-pay proposal: 200.1M for, 2.5M against, 0.3M abstain, 33.3M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95853,"accession_number":"0001823239-26-000022","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.","Adjusted EBITDA of $20.3M vs $(10.5)M prior year; generated $4.2M free cash flow.","TriLink revenue up 65.1% to $47.5M, driven by $14.3M COVID CleanCap orders; base TriLink up 15.4%.","Cygnus revenue $18.4M, up 1.4% due to strong North America/EMEA, offset by China timing.","Full-year 2026 revenue and Adjusted EBITDA guidance raised reflecting Q1 strength and improved visibility."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":65837000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109203,"accession_number":"0001823239-26-000005","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q4 revenue $49.9M, net loss $63M; guides 2026 revenue $200-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $49.9M, net loss $(63.0)M, positive Adj EBITDA $0.5M (non-GAAP).","Full year 2025 revenue $185.7M, net loss $(230.8)M, Adj EBITDA $(31.2)M.","Introduces 2026 revenue guidance $200M-$210M and Adj EBITDA guidance $18M-$20M.","CEO cites strong execution, exceeding revenue expectations, returning to positive Adj EBITDA.","Organizational restructuring and operating cost reduction ahead of plan."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":185743000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125698,"accession_number":"0001823239-25-000117","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q3 revenue $41.6M, net loss $45.1M, Adj EBITDA -$10.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $41.6 million, net loss of $45.1 million, and Adjusted EBITDA loss of $10.8 million for Q3 2025.","Full-year 2025 revenue guidance of approximately $185 million, excluding potential high-volume CleanCap orders.","CEO expects double-digit sequential revenue growth in Q4 2025, citing strong funnel and order velocity at TriLink.","Organizational restructuring and operating cost reduction initiatives remain on track."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":135877000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125697,"accession_number":"0001823239-25-000113","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Maravai LifeSciences reduces board from 11 to 8; three directors resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Benjamin Daverman, Jessica Hopfield, and Murali Prahalad resigned from the Board effective Oct 21, 2025.","Board size reduced from 11 to 8 directors effective Oct 27, 2025; resignations were not due to any disagreement.","R. Andrew Eckert named chair of Nominating, Governance and Risk Committee and member of Audit Committee.","Gregory T. Lucier appointed to Nominating, Governance and Risk Committee; unvested RSUs for departing directors accelerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142427,"accession_number":"0001823239-25-000105","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","2.05","5.02","9.01"],"status":"ready","headline":"Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.","Announced restructuring targeting >$50M annualized savings; workforce reduction of ~25% with $8-9M severance costs.","Withdrew 2025 revenue guidance pending new leadership's business review.","CEO Bernd Brust recently appointed; EVP CCO Rebecca Buzzeo and EVP CAO Pete Leddy departing.","Base business revenue (ex high-volume CleanCap) grew 5% YoY; positive free cash flow expected by H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":94247000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142426,"accession_number":"0001823239-25-000099","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Maravai LifeSciences dismisses EY, appoints Deloitte; material weakness disclosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EY dismissed as auditor; Deloitte appointed effective July 16, 2025 for FY 2025.","EY's audit reports on financial statements for 2023 and 2024 were unqualified.","EY's internal control report for 2024 contained an adverse opinion citing material weaknesses in revenue/AR and goodwill impairment.","No disagreements on accounting principles or reportable events other than the internal control weakness.","Company did not consult Deloitte before the appointment; EY letter filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160466,"accession_number":"0001193125-25-146905","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai LifeSciences appoints Rajesh Asarpota as CFO effective June 30, 2025, succeeding Kevin Herde","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajesh Asarpota appointed EVP and CFO effective June 30, 2025; Kevin Herde transitions to advisory role through Jan 31, 2026.","Asarpota receives $550k base salary, 70% target bonus, $200k cash sign-on bonus, and equity awards (333,333 options, 500k RSUs, 750k PSUs).","Previous CFO Kevin Herde entitled to severance payments per May 2023 employment agreement upon signing separation agreement.","Company not reaffirming or withdrawing FY2025 guidance; will review during Q2 2025 earnings call in August."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160465,"accession_number":"0001193125-25-137478","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai LifeSciences appoints Bernd Brust as CEO, succeeding William Martin","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bernd Brust named CEO and board member effective June 8, 2025; William Martin resigned as CEO and from board.","Brust's base salary is $750,000 with a target annual cash bonus of 100% of base salary.","Equity awards: 1M stock options, 2M RSUs, 2.25M PSUs; options and RSUs vest over three years.","Martin's departure not due to any disagreement; he is eligible for severance per existing agreement.","Company will revisit FY2025 guidance in August Q2 earnings call after Brust's assessment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160464,"accession_number":"0001823239-25-000065","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Maravai shareholders elect 4 directors, ratify EY, approve say-on-pay at 2025 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Sean Cunningham, John DeFord, Jessica Hopfield, Murali Prahalad as directors for three-year terms; each received over 88% of votes cast.","Ratified Ernst & Young as independent auditor for FY2025 with 230M votes for, 457K against, 1.2M abstentions.","Advisory say-on-pay approved with 169.5M votes for, 37.4M against, 2.6M abstentions; broker non-votes 22.2M.","Quorum established with 231.7M shares present out of 254.6M outstanding as of March 24, 2025 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160463,"accession_number":"0001823239-25-000062","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q1 revenue $46.9M (-27% YoY), net loss $(52.9)M, adj EBITDA $(10.5)M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $46.9M vs $64.2M in Q1 2024; net loss $(52.9)M includes $12.4M goodwill impairment.","Adjusted EBITDA fell to $(10.5)M from $7.8M in prior-year quarter.","Nucleic Acid Production revenue $28.8M (-37.5% YoY) on lack of high-volume CleanCap orders; Biologics Safety Testing $18.1M (flat YoY).","Full-year 2025 revenue guidance maintained at $185M-$205M, excluding potential high-volume CleanCap vaccine orders.","Base business (ex CleanCap vaccine) grew >$4M sequentially from Q4 2024, per CEO Trey Martin."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":46850000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178715,"accession_number":"0001823239-25-000059","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Maravai LifeSciences guides 2025 revenue $185M-$205M; Q1 revenue $43M-$45M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2025 revenue guidance $185M-$205M; Q1 2025 revenue $43M-$45M.","Adjusted EBITDA excludes interest ($14-16M), D&A ($50-55M), stock-based comp ($45-50M).","Fully diluted shares ~256M; capex expected $15M-$20M in 2025.","Guidance excludes impact of potential new acquisitions or unquantified items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178714,"accession_number":"0001823239-25-000033","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","4.02","9.01"],"status":"ready","headline":"Maravai restates Q2/Q3 2024 financials due to $3.9M revenue recognition error; Q4 revenue down 24%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on Q2 and Q3 2024 financials; restatement corrects $3.9M revenue timing error.","Q4 revenue $56.6M (-23.7% YoY); Adjusted EBITDA loss of $1.1M vs +$20.5M a year ago.","Full year 2024 revenue $259.2M (-10.3% YoY); net loss $259.6M includes $166M goodwill impairment.","Voluntarily prepaid $228M of Term Loan with cash; year-end cash $322M.","Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178713,"accession_number":"0001823239-25-000028","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Maravai postpones Q4/FY2024 earnings, cites material weakness in revenue recognition and potential goodwill impairment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Earnings release and call postponed; 10-K filing delayed until March 18, 2025.","Preliminary FY2024 revenue near midpoint of $255M-$265M guidance.","Additional time needed for goodwill impairment assessment related to Alphazyme LLC acquisition.","Revenue recognition error for ~$3.9M shipment recorded in wrong quarter; no full-year impact.","Assessing effectiveness of internal controls; material weakness in revenue recognition identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178712,"accession_number":"0001823239-25-000002","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Maravai expects 2024 revenue near midpoint of $255M-$265M; President of Nucleic Acid Production departs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited 2024 revenue expected near midpoint of $255M-$265M guidance range.","Andrew Burch, President of Nucleic Acid Production, position eliminated; last day Jan 16, 2025.","CEO Trey Martin will assume direct responsibility for Nucleic Acid Production segment.","Q4 and full year 2024 earnings release scheduled for Feb 25, 2025 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195382,"accession_number":"0001823239-24-000133","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Maravai prepays $228M of term loan; remaining balance ~$300M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Voluntarily prepaid $228M aggregate principal of term loan using cash on hand.","Remaining term loan principal balance after prepayment is approximately $300M.","No prepayment penalties incurred on the prepayment.","$167M in aggregate borrowing capacity remains available under the revolver.","Prepayment reduces debt and future interest expense; no change to credit agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195381,"accession_number":"0001823239-24-000124","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai LifeSciences Chairman Carl Hull Retires; R. Andrew Eckert Appointed Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Founder Carl Hull retires as Executive Chairman and resigns from Board, effective Dec 5, 2024; departure not related to any disagreement.","R. Andrew Eckert unanimously elected Chairman of the Board, effective Dec 5, 2024; he is a healthcare industry veteran with prior executive roles.","Eckert receives annual cash retainer of $175,000 (starting Jan 1, 2025) and RSU awards with total grant date fair value of $1.25M, subject to vesting.","Initial RSU award of $750K vests one-third immediately, remainder at 2025 annual meeting and one year later; second award of $500K expected at 2025 annual meeting.","Carl Hull founded Maravai in 2014, served as CEO until Oct 2022 when he became Executive Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195380,"accession_number":"0001823239-24-000105","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai reports Q3 loss of $176M on $154.2M goodwill impairment; acquires Officinae Bio DNA/RNA business","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $65.2M (down 2.5% YoY); net loss $(176.0)M includes $154.2M goodwill impairment.","Adjusted EBITDA $12.7M vs $11.9M in Q3 2023.","FY2024 revenue guidance lowered to $255-265M (from prior outlook).","Agreed to acquire Officinae Bio's DNA/RNA business (AI-driven platform); close expected early 2025.","Nucleic Acid Production revenue $49.9M (down 2.5% YoY); Biologics Safety Testing $15.3M (down 2.5%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":202779000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211640,"accession_number":"0001823239-24-000100","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Maravai extends $167M revolver maturity by five years via credit amendment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maravai entered Third Amendment on Sep 10, 2024 to extend $167M revolver maturity from Oct 2025 to five years later, subject to springing maturity tied to term loan (Oct 2027).","Revolving facility remains undrawn; amendment effective upon customary conditions including 0.65% commitment fee on $167M facility.","If conditions not satisfied or waived by Oct 8, 2024, amendment will not take effect and no fee is due.","Amendment also terminates AXA's commitment and converts all existing revolver commitments to extended commitments under new terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211639,"accession_number":"0001823239-24-000093","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q2 revenue up 6.5% to $73.4M, net loss $14.5M; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $73.4M (+6.5% YoY); Nucleic Acid Production +9.8%, Biologics Safety Testing -4.7%.","Net loss $(14.5)M vs $(11.9)M prior year; Adjusted EBITDA $16.9M up from $9.1M.","H1 2024 revenue $137.6M (-7% YoY); net loss $(37.2)M vs $(13.3)M.","Reaffirms FY2024 revenue guidance $265M-$285M.","Business updates: TriLink-Johns Hopkins collaboration, Flanders facilities milestones, new product launches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":137579000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211638,"accession_number":"0001823239-24-000091","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai CEO Trey Martin appointed to Board of Directors, effective July 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO William 'Trey' Martin III appointed as Class III director, effective July 31, 2024.","Appointment fills Board vacancy created by Anat Ashkenazi's previously-reported resignation.","Martin receives no additional compensation for Board service; retains existing CEO compensation.","Term runs until 2026 annual meeting; Martin is one of two executives on the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230356,"accession_number":"0001823239-24-000084","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Anat Ashkenazi to resign from Maravai board on July 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anat Ashkenazi notified Board of resignation effective July 31, 2024.","Resignation due to time commitments for pending CFO role at Alphabet Inc.","Company states resignation not related to any disagreement with management or Board.","No replacement director announced; search process not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230355,"accession_number":"0001823239-24-000082","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Maravai shareholders elect directors, ratify auditor, approve executive compensation at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected four director nominees: Benjamin Daverman, Susannah Gray, Carl Hull, Constantine Mihas to three-year terms.","Ratified Ernst & Young LLP as independent auditor for FY 2024 with 236,288,478 votes for, 268,742 against.","Non-binding advisory approval of named executive officer compensation with 223,303,654 votes for.","Quorum met with 236,931,940 shares represented out of 251,748,827 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230354,"accession_number":"0001823239-24-000058","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q1 revenue down 19% to $64.2M; net loss widens to $22.7M; FY guide reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Quarterly revenue $64.2M, down 19% YoY; Nucleic Acid Production fell 25% to $46.0M.","Net loss of $22.7M vs $1.3M loss in Q1 2023; Adjusted EBITDA $7.8M vs $23.8M.","Biologics Safety Testing revenue up 3.4% to $18.2M.","Reaffirmed FY2024 revenue guidance $265M–$285M.","Entered non-exclusive CleanCap license agreement with Lonza for mRNA services."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":64179000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248764,"accession_number":"0001823239-24-000028","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q4 revenue plunges 64% to $74.1M; net loss $110M; FY24 guidance $265-285M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $74.1M (down 64% YoY); net loss $110M vs net income $87.4M year ago.","Nucleic Acid Production revenue $58.8M in Q4, down 69% YoY; COVID CleanCap revenue fell $105M YoY.","Full year 2023 revenue $288.9M (down 67% YoY); net loss $138.4M vs net income $490.7M.","Introduced 2024 revenue guidance of $265M-$285M, below 2023 actual.","Announced CleanCap patent awards in China/Canada, supply deal with FUJIFILM Toyama Chemical, and Cygnus-Dyadic partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":288945000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266251,"accession_number":"0001823239-23-000087","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q3 revenue down 65% to $66.9M, net loss of $15.1M; cuts ~100 jobs to save $30M annually","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $66.9M (-65% YoY); net loss $15.1M vs net income $99.7M a year ago.","Nucleic Acid Production revenue $51.2M (-71% YoY); COVID-19 CleanCap demand fell $111.6M from prior year.","Cost realignment targets $30M annual savings, workforce reduction of ~15% (~100 employees) with $5M one-time severance.","Full-year 2023 guidance lowered to revenue $275-285M; Adjusted EBITDA margin 18% in Q3.","Partnerships with Thermo Fisher, Intellia, Elixirgen, Precision BioSciences for mRNA cap analogs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":214804000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283515,"accession_number":"0001823239-23-000079","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q2 revenue $68.9M, down 72%; net loss $11.9M; CEO transition to Trey Martin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $68.9M, down 71.6% YoY; net loss $(11.9)M vs net income $156.7M prior year.","Nucleic Acid Production revenue $53.3M (-76.4%), including $11.6M CleanCap; Biologics Safety Testing $15.6M (-10.5%).","Appointed Trey Martin as CEO effective July 27, 2023; Carl Hull remains Executive Chair.","Took occupancy of new 32,000-sq-ft cGMP mRNA facility in San Diego; expanded enzyme R&D in Florida.","Updated 2023 financial guidance conservatively; no specific numbers provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":147939000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283514,"accession_number":"0001823239-23-000077","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai LifeSciences completes planned CEO succession; Martin becomes CEO, Hull Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William 'Trey' Martin, III named CEO effective July 27, 2023; previously President of Biologics Safety Testing segment.","Carl Hull transitions from interim CEO to Executive Chairman; annual base salary reduced to $500,000.","Hull's target annual bonus set at 100% of salary for 2024+; 2023 target remains $757,667.","Martin's compensation unchanged from his prior role as President of Biologics Safety Testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283513,"accession_number":"0001823239-23-000072","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai LifeSciences announces director resignation and appointment of Dr. John DeFord to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert B. Hance resigned from Board effective July 19, 2023; resignation unrelated to any disagreement with management.","Dr. John DeFord appointed to Board effective July 20, 2023 to fill vacancy; will serve as Class II director through 2025 annual meeting.","DeFord is Chairman, CEO and President of Samothrace Medical Innovations; former EVP & CTO of Becton, Dickinson and Company.","DeFord also serves on boards of Nordson Corporation, NuVasive, and several private medical device companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303004,"accession_number":"0001823239-23-000041","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Maravai LifeSciences shareholders elect three Class III directors at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Anat Ashkenazi, Gregory T. Lucier, and Luke Marker elected as Class III directors with over 183M votes each.","Ratification of Ernst & Young as independent auditor for 2023 passed with 234,840,684 votes for, 15,103 against.","Non-binding advisory vote on executive compensation approved: 221,869,456 for, 8,907,696 against.","Quorum present: 234,865,441 of 250,882,769 outstanding shares, representing approximately 93.6%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303003,"accession_number":"0001823239-23-000037","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q1 revenue $79M, down 68% YoY; net loss $1.3M vs prior net income $146.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $79.0M, -67.7% YoY; net loss $(1.3)M vs net income $146.9M in Q1 2022.","Nucleic Acid Production revenue $61.5M (-72.5% YoY) includes ~$15.9M COVID-19 CleanCap revenue, $157M less YoY.","Biologics Safety Testing revenue $17.6M (-14.9% YoY) driven by post-COVID inventory normalization and China slowdown.","Adjusted EBITDA $23.8M (30.1% margin), down from $187.0M in prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":79025000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322637,"accession_number":"0001823239-23-000020","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Maravai LifeSciences COO Brian Neel Resigns; Andrew Burch Named Successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Neel resigned as COO, Nucleic Acid Production, effective March 31, 2023.","Andrew Burch, formerly of Thermo Fisher Scientific, appointed EVP and General Manager of Nucleic Acid Products Division.","Burch will assume his role after Neel's departure on March 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322636,"accession_number":"0001823239-23-000017","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Maravai LifeSciences confirms no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company has no cash deposits or securities at Silicon Valley Bank.","Company has no lending relationship or other business with SVB.","Disclosure made on March 10, 2023 amid SVB's collapse and market concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322635,"accession_number":"0001823239-23-000012","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q4 revenue $204.7M, adj EPS $0.35; 2023 guidance $420-460M; acquires Alphazyme","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $204.7M (-10% YoY); net income $87.4M; adjusted diluted EPS $0.35.","Full year 2022 revenue $883.0M (+10% YoY); net income $490.7M; adjusted EPS $1.80.","Base business revenue (ex-COVID CleanCap) up 67% in Q4 and 17% full year.","2023 revenue guidance $420M-$460M; base business growth expected >20%.","Acquired Alphazyme, LLC (private enzyme manufacturer); announced CEO succession plan."],"consensus_eps_estimate":null,"consensus_eps_actual":1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":883001000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340661,"accession_number":"0001193125-22-296553","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai settles noncompete lawsuit; Martin to become President, then CEO in July 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trey Martin to serve as President of Biologics Safety Testing segment from Dec 5, 2022.","Martin expected to become CEO on July 27, 2023, per settlement with Danaher entities.","Settlement limits Martin's responsibilities and bars involvement in Nucleic Acid Production segment until July 26, 2023.","Carl Hull continues as Executive Chairman and interim CEO; lawsuit voluntarily dismissed.","Christine Dolan remains COO of Biologics Safety Testing segment, reporting to Martin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340660,"accession_number":"0001823239-22-000056","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q3 revenue $191.3M, down 7% YoY; net income $99.7M; guidance updated","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q3 revenue $191.3M (-6.6% YoY); net income $99.7M vs $132.2M prior year.","Adjusted EBITDA $132.5M (69% margin), down from $154.9M prior year.","Nucleic Acid Production revenue $174.9M, down 4% YoY; COVID-19 CleanCap revenue estimated $126.5M.","Biologics Safety Testing revenue $16.4M, down 1% YoY.","FY2022 guidance updated for revenue, Adjusted EBITDA, and Adjusted EPS; specific figures not provided in excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":678288000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340659,"accession_number":"0001823239-22-000052","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-10-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CEO Trey Martin placed on paid leave after court-ordered noncompete TRO; Carl Hull named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Delaware Court of Chancery issued TRO preventing Martin from working for Maravai; pending preliminary injunction hearing later this year.","Danaher subsidiaries filed suit alleging Martin breached noncompete agreement from prior employment.","Carl Hull, former CEO and current Executive Chairman, appointed interim CEO to manage day-to-day operations.","Martin remains on paid leave with same compensation package pending resolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340658,"accession_number":"0001823239-22-000048","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Maravai names Trey Martin CEO, co-founder Carl Hull becomes Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin appointed CEO effective Sept 30, 2022, succeeding Carl Hull who becomes Executive Chairman.","Martin previously SVP at Danaher, President of Integrated DNA Technologies; over 25 yrs in life sciences.","Martin receives base salary $750k, target bonus $937.5k for 2022, and equity awards totaling ~$17M.","Hull's base salary reduced to $500k; target bonus for 2022 remains $725k, subsequent years 100% of base.","Company to discuss transition on Q3 2022 earnings call scheduled for Nov 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357901,"accession_number":"0001823239-22-000042","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q2 revenue $242.7M (+11% YoY), net income $156.7M (+17%), Adj. EBITDA margin 78% record","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q2 revenue $242.7M (+11% YoY); net income $156.7M (+17%); Adj. EBITDA $188.5M (78% margin).","Nucleic Acid Production revenue $225.2M (+17% YoY); base business (ex-COVID CleanCap) grew 27%.","Biologics Safety Testing revenue $17.5M (-4% YoY); Protein Detection business sold in Sept 2021.","Leadership additions: Pete Leddy as EVP/CAO, Kate Broderick SVP R&D, Jay Lochhead VP Quality & Regulatory.","Signed DoD cooperative agreement to partly fund Nucleic Acid Production manufacturing expansion in San Diego."],"consensus_eps_estimate":null,"consensus_eps_actual":1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":487025000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376559,"accession_number":"0001823239-22-000020","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Maravai shareholders elect directors, ratify auditor, back annual say-on-pay at 2022 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected four Class II directors: Cunningham, Hance, Hopfield, Prahalad, each with >206M votes for.","Ratified Ernst & Young as independent auditor for FY2022; 238.2M votes for, 9,858 against.","Shareholders recommended annual say-on-pay votes (234.4M for every year); board adopts annual frequency.","Quorum of 238.2M shares present out of 255.2M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376558,"accession_number":"0001823239-22-000015","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q1 revenue $244.3M (+65% YoY); net income $146.9M; raises FY22 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 revenue $244.3M, up 65% YoY; Nucleic Acid Production $223.7M (+80%).","Net income $146.9M (+95% YoY); Adjusted EBITDA $187.0M (77% margin).","Nucleic Acid Production base business (ex-COVID CleanCap) revenue grew 55% YoY.","Full-year 2022 revenue guidance reaffirmed; Adjusted EBITDA and EPS guidance raised.","Deborah Barbara appointed Vice President, Business Development and Strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":244293000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394909,"accession_number":"0001823239-22-000008","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q4 revenue $228M, up 132% YoY; net income $127M; 2022 guidance raised to $920-960M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $228.4M (+132% YoY); net income $127.1M (+778% YoY).","FY2021 revenue $799.2M (+181% YoY); net income $469.3M; adjusted EBITDA $582.8M.","Nucleic Acid Production segment Q4 revenue $212.5M (+173% YoY) driven by CleanCap demand for mRNA vaccines.","2022 revenue guidance raised to $920M-$960M, implying 15-20% growth over 2021 record.","Completed debt repricing saving ~$6.8M annually in interest; acquired MyChem for ultra-pure nucleotides."],"consensus_eps_estimate":null,"consensus_eps_actual":1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":799240000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394908,"accession_number":"0001823239-22-000006","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-01-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Maravai acquires MyChem for $240M cash; expands ultra-pure nucleotides for mRNA therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $240M cash at close plus contingent consideration based on future conditions.","MyChem provides ultra-pure nucleotides for diagnostics, pharma, genomics; complements Maravai's TriLink mRNA technologies.","MyChem to become part of TriLink's Nucleic Acid Production segment; founder-led team stays on.","Deal strengthens Maravai's end-to-end mRNA supply chain and adds GMP manufacturing capability.","Advisors: Jefferies & Kirkland & Ellis for Maravai; BroadOak & Morrison & Foerster for MyChem."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394907,"accession_number":"0001823239-22-000004","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-01-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Maravai amends credit agreement; replaces LIBOR with SOFR, reduces interest margins, and refinances $544M term loans.","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment replaces LIBOR with Term SOFR; interest margin on Term SOFR loans reduced to 3.00% from 3.75%-4.25%.","Base rate floor for term loans lowered from 2.00% to 1.50%; Term SOFR floor set at 0.50% (term) and 0.00% (revolving).","New $544M Tranche B Term Loan facility refinances existing $600M Initial Term Loans via cashless conversion or new lender commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394906,"accession_number":"0001823239-22-000002","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Maravai contributes $110M to Topco, forfeits units; voting power shifts to 51.5%/48.5%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Contributed $110M to Topco for 2,732,919 Common Units at $40.25/unit (50-day VWAP).","Company forfeited 2,732,919 Common Units and MLSH 1 forfeited 2,570,415 Common Units and equal Class B shares for no consideration.","Resultant voting power: Class A holders 51.5% (was 51.0%), MLSH 1 48.5% (was 49.0%).","Transaction reduces excess cash from Up-C tax distributions, making cash accessible to operating companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413593,"accession_number":"0001823239-21-000025","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maravai Q3 revenue up 133% to $204.8M; raises 2021 guidance, provides 2022 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $204.8M (+133% YoY); net income $132.8M (+240%); Adj EBITDA $156.0M.","Nucleic Acid Production revenue $182.9M (+170% YoY) on demand for CleanCap mRNA vaccine components.","2021 guidance raised: revenue $770-780M, Adj EBITDA $570-575M, Adj diluted EPS $1.48-$1.52.","Initial 2022 revenue guidance $840-880M, representing ~11-14% growth at midpoint after adjusting for divestiture.","Completed sale of Protein Detection business; published inaugural ESG report."],"consensus_eps_estimate":null,"consensus_eps_actual":1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":570796000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432095,"accession_number":"0001823239-21-000023","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2021-09-03T23:59:59+00:00","items":["1.01","2.01","9.01"],"status":"ready","headline":"Maravai closes sale of Protein Detection segment; amends Pfizer/BioNTech supply pact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of Vector Laboratories (Protein Detection) to Voyager Group/Thompson Street on Sept 2, 2021.","Disposition not considered a significant business; Vector CEO Lisa Sellers leaves Maravai.","Amendment to TriLink supply agreement with Pfizer and BioNTech shifts invoicing to shipment-based from milestone-based.","Amendment effective June 6, 2021; redacted pricing/billing terms included.","Deal amendments clarify payments for facility relocation and exclude certain payables from purchase price adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432094,"accession_number":"0001823239-21-000018","cik":1823239,"company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","ticker":"MRVI","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Maravai Q2 revenue up 364% to $217.8M, raises FY guidance to $745-770M; selling Vector for $124M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $217.8M (+364% YoY); net income $134.3M vs $1.4M; Adj. EBITDA $164.7M vs $17.5M.","Nucleic Acid Production revenue $192.5M (+532.8% YoY) driven by CleanCap demand for COVID-19 vaccines.","Divested Protein Detection segment (Vector) for $124M cash to Thompson Street Capital Partners; close expected Q3 2021.","2021 revenue guidance raised to $745-770M from prior; reflects robust demand for Nucleic Acid Production.","Facility expansions: new San Diego site to boost mRNA capacity; Biologic Safety Testing moving to larger Leland, NC site."],"consensus_eps_estimate":null,"consensus_eps_actual":0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":365986000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1181219902.2254004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}